Magnetic Fields / P53 Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱

Features: Therapy

Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Reactive oxygen species (ROS)	↑ ROS (P→R); often sustained (G)	↑ ROS (P); ↔/↓ net ROS (R→G)	P, R, G	Upstream redox perturbation	MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2	NRF2 antioxidant response	↔ / insufficient NRF2 induction (R→G)	↑ NRF2 activation (R→G)	R, G	Adaptive redox defense	Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3	Glutathione (GSH) homeostasis	↓ GSH (R→G)	↔ or transient ↓ (R) with recovery (G)	R, G	Redox buffering capacity	GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4	Superoxide dismutase (SOD) / antioxidant enzymes	↔ or inadequate enzyme upshift (G)	↑ SOD/GPx/CAT capacity (G)	G	Longer-term antioxidant remodeling	Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5	Mitochondrial ETC / respiration	↓ ETC efficiency; ↑ electron leak (P→R)	↔ mild, reversible ETC perturbation (P→R)	P, R	Bioenergetic destabilization	ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6	Mitochondrial membrane potential (ΔΨm / MMP)	↓ ΔΨm (R); may progress (G)	↔ preserved or reversible dip (R)	R, G	Mitochondrial dysfunction thresholding	ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7	Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux)	↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G)	↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G)	P, R, G	Stress signal amplification	Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8	Mitochondrial permeability transition pore (MPTP)	↑ MPTP opening propensity (R); sustained opening possible (G)	↔ transient or closed (R→G)	P, R, G	Commitment point for mitochondrial failure	MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9	ER stress / UPR	↑ ER stress (R); CHOP-commitment possible (G)	↑ adaptive UPR (R); resolves (G)	R, G	Proteostasis stress	Often downstream of ROS + Ca²⁺ handling perturbations
10	DNA damage (oxidative)	↑ damage markers (R→G)	↔ or repaired (G)	R, G	Checkpoint pressure	Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11	LDH / glycolytic flux	↓ glycolytic performance (R→G)	↔ flexible substrate switching (R→G)	R, G	Metabolic vulnerability	Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12	Thioredoxin system (Trx / TrxR)	↓ functional reserve / overload (R→G)	↔ preserved capacity (G)	R, G	Parallel antioxidant system stress	Useful when GSH-only does not explain redox phenotype

Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)

MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.

P53, P53-Guardian of the Genome: Click to Expand ⟱

Source: TCGA

Type: Proapototic

TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.

Scientific Papers found: Click to Expand⟱

356-

AgNPs,

MF,

Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study

in-vitro,

BC,

MCF-7

 10 µM/ml + 1mT,2hr

 likely 50-60Hz and 1mT

in-vitro,

Bladder,

HTB-22

4uM/ml

 calculated IC50 value of AgNPs was 4.15 ± 0.20 μM/ml

Apoptosis↑, P53↑, iNOS↑, NF-kB↑, Bcl-2↓, ROS↑, SOD↑, TumCCA↑, eff↑, Catalase↑, other↑,

400-

AgNPs,

MF,

Polyvinyl Alcohol Capped Silver Nanostructures for Fortified Apoptotic Potential Against Human Laryngeal Carcinoma Cells Hep-2 Using Extremely-Low Frequency Electromagnetic Field

in-vitro,

Laryn,

HEp2

50mT/30mins

3.29 0.4 mol/mL

6x improvement when LEMF added (50mT/15mins)

TumCP↓, Casp3↑, P53↑, Beclin-1↑, TumAuto↑, GSR↑, ROS↑, MDA↑, ROS↑, SIRT1↑, Ca+2↑, Endon↑, DNAdam↑, Apoptosis↑, NF-kB↓,

402-

AgNPs,

MF,

Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study

in-vitro,

BC,

MCF-7

10 µM/ml+EMF(1mT)

4.15 μM/ml for AgNPs

P53↑, iNOS↑, NF-kB↑, Bcl-2↓, miR-125b↓, ROS↑, SOD↑,

401-

GoldNP,

MF,

In vitro evaluation of electroporated gold nanoparticles and extremely-low frequency electromagnetic field anticancer activity against Hep-2 laryngeal cancer cells

in-vitro,

Laryn,

HEp2

50mT/15mins

4.79 μg/mL IC50 for Au-NP

Casp3↑, P53↑, BAX↑, Bcl-2↓,

3464-

MF,

Progressive Study on the Non-thermal Effects of Magnetic Field Therapy in Oncology

Review,

Var,

AntiTum↑, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↑, Diff↑, angioG↓, TumMeta↓, EPR↑, ChemoSen↑, ROS↑, DNAdam↑, P53↑, Akt↓, MAPK↑, Casp9↑, VEGFR2↓, P-gp↓,

200-

MFrot,

MF,

Moderate intensity low frequency rotating magnetic field inhibits breast cancer growth in mice

in-vivo,

BC,

MDA-MB-231

 0–0.15 T. rotating frequency  2.5 Hz, 3.3 Hz and 4.2 Hz

mice; inhibit tumor growth 30%

in-vivo,

BC,

MCF-7

ALAT↓, TumVol↓, TumCCA↑, TumCG↓, TumMeta↓, Imm↑, P53↑, ALAT↓, AST↓,

222-

MFrot,

MF,

LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway

in-vitro,

Lung,

A549

 0.4T, 7.5 Hz

 inhibits iron metabolism

TumCG↓, OS↑, miR-34a↑, E2Fs↓, P53↑, TfR1/CD71↓, Ferritin↓,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes ⓘ

AntiTum↑, 1, OS↑, 1, TumVol↓, 1,
Total Targets: 47

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome

7 Magnetic Fields
3 Silver-NanoParticles
2 Magnetic Field Rotating
1 Gold NanoParticles

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

Magnetic Fields / P53 Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Metal & Cofactor Biology ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Home Page